Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation

Journal of Clinical Psychiatry

Volumn 75, Issue 5, 2014, Pages

  Beach, Scoff R ^a   Kostis, William J ^a   Celano, Christopher M ^a   Januzzi, James L ^a   Ruskin, Jeremy N ^a   Noseworthy, Peter A ^a   Huffman, Jeff C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FACTUAL DATABASE; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; QT INTERVAL; QT PROLONGATION; RISK BENEFIT ANALYSIS; RISK FACTOR; SAMPLE SIZE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; HUMANS; LONG QT SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 84901714421     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13r08672     Document Type: Article

References (56)

1. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5(1):97-104.
2. Fossa AA, Gorczyca W, Wisialowski T, et al. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods. 2007;55(1):78-85. (Pubitemid 46048674)
3. Rautaharju PM, Surawicz B, Gettes LS, et al; Heart Rhythm Society. AHA/ ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation. 2009;119(10):e241-e250.
4. Viskin S, Justo D, Halkin A, et al. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45(5):415-427. (Pubitemid 36403114)
5. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. J Clin Psychiatry. 1998;59(suppl 15):13-18. (Pubitemid 28467473)
6. Glassman AH, Rodriguez Al, Shapiro PA. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry. 1998;59(suppl 10):16-21. (Pubitemid 28388051)
7. Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1-13.
8. Food and Drug Administration. FDA safety communication: abnormal heart arrhythmias associated with high doses of Celexa (citalopram hydrobromide); August 24,2011. http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm. Updated March 28,2012. Accessed February 6,2014.
9. Food and Drug Administration. FDA safety communication: revised recommendations for (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses; March 28,2012. http://www.fda.gov/Drugs/ DrugSafety/ucm297391.htm. Updated February 15,2013. Accessed February 6,2014.
10. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses. Lancet. 1999;354(9193):1896-1900.
11. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008- 2012. (Pubitemid 30214957)
12. Robinson JF, Doogan DP. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers. Br J Clin Pharmacol. 1982;14(6):805-808. (Pubitemid 13195429)
13. Upward JW, Edwards JG, Goldie A, et al. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol. 1988;26(4):399-402.
14. Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. (Pubitemid 27047257)
15. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155(5):660-665. (Pubitemid 28225407)
16. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62(6):783-789. (Pubitemid 32009084)
17. Edwards JG, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology (Berl). 1989;97(1):96-98. (Pubitemid 19020389)
18. Kuhs H, Rudolf GA. Cardiovascular effects of paroxetine. Psychopharmacology (Berl). 1990;102(3):379-382. (Pubitemid 20335066)
19. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287-291. (Pubitemid 28071019)
20. Yeragani VK Pohl R, Jampala VC, et al. Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder. Depress Anxiety. 2000;11(3):126-130. (Pubitemid 30347189)
21. Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry. 2006;8(4):212-219. (Pubitemid 44371559)
22. Fisch C, Knoebel SB. Electrocardiographic findings in sertraline depression trials. Druglnvest. 1992;4(4):305-312.
23. Glassman AH, O'Connor CM, Califf RM, et al; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709. (Pubitemid 34848222)
24. Slavícek J, Paclt I, Hamplová J, et al. Antidepressant drugs and heart electrical field. Physiol Res. 1998;47(4):297-300. (Pubitemid 28404968)
25. Lespérance F, Frasure-Smith N, Koszycki D, et a; CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367-379. (Pubitemid 46155798)
26. Forest Laboratories. Evaluation of the effects of sequential multiple-dose regimens of escitalopram on cardiac repolarization in healthy subjects, 2012.
27. http://www.forestclinicaltrial.com/CTR/CTRCController/CTRViewPdf? -file-id=scsr/SCSR-SCT-PK-21-flnal.pdf. Accessed September 23, 2012.
28. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384. (Pubitemid 28438523)
29. Huf W, Kalcher K, Kasper S. Widespread methodological problems limit validity of meta-analytic results. Psychother Psychosom. 2011;80(4):246, author reply 247-248.
30. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101-129.
31. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
32. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86(3):638-641.
33. Orwin RG. A Fail-safe N for effect size in meta-analysis. J Educ Stat. 1983;8(2):157-159.
34. Alderman J. Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin Ther. 2005;27(7):1050-1063. (Pubitemid 41262463)
35. Rasmussen SL, Overa KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol. 1999;19(5):407-415. (Pubitemid 29451505)
36. de la Torre BR, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther DrugMonit. 2001;23(4):435-440. (Pubitemid 32708931)
37. van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29(1):9-15.
38. Warrington SJ, Dana-Haeri J, Sinclair AJ. Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand suppl. 1989;80(S350):42-44. (Pubitemid 19236636)
39. Pohl R, Balon R, Jayaraman A, et al. Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. J Psychosom Res. 2003;55(3):247-251. (Pubitemid 38366227)
40. Betapace (sotalol HC1) [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals. 2010. http://www.accessdata.fda.gov/dragsatfda-docs/label/201l/ 019865s019lbl.pdf. Accessed February 6,2014.
41. Milnes JT, Crociani 0, Arcangeli A, et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol. 2003;139(5):887-898. (Pubitemid 36877388)
42. Thomas D, Gut B, Wendt-Nordahl G, et al. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther. 2002j300(2):543-548.
43. Witchel HJ, Pabbathi VK, Hofmann G, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 2002;512(l-3):59-66. (Pubitemid 34164451)
44. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62-69. (Pubitemid 38134167)
45. Demolis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation. 1996;94(7):1592-1599. (Pubitemid 26320263)
46. Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol. 1989;64(18):1138-1143. (Pubitemid 19279990)
47. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(suppl 1):19-23.
48. Roden DM. Drug-induced prolongation of the QT interval. NEngl J Med. 2004;350(10):1013-1022. (Pubitemid 38269278)
49. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45(5):371-377. (Pubitemid 39166908)
50. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drags and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687-693.
51. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346(3):f288.
52. Muldoon C. The safety and tolerability of citalopram. Int Clin Psychopharmacol. 1996;11(suppl 1):35-40.
53. Muldoon CG. Citalopram: Monitoring the QTc Interval, Report #3. Copenhagen, Denmark: Lundbeck; 1995.
54. Overo KF. In: Montgomery SA, ed. Citalopram: a New Antidepressant From Lundbeck Research. Amsterdam, The Netherlands: ExcerptaMedica; 1999:22-30.
55. Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes: how should we apply the recent FDA ruling? Am J Med. 2012;125(9):859-868.
56. Jiang W, O'Connor C, Silva SG, et al SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008;156(3):437-444.